Clinuvel Pharmaceuticals Ltd has released a press release.
S&P DJI Announces September 2018 Quarterly Rebalance
Clinuvel Pharmaceuticals Limited on 6ix
Earlier from Clinuvel Pharmaceuticals
- US FDA Update
- CLINUVEL completes SCENESSE FDA Filing
- NICE maintains position not to recommend SCENESSE
- CLINUVEL Regulatory Update
- CLINUVEL to take 100% ownership of VALLAURIX joint venture
Later from Clinuvel Pharmaceuticals
- Appeal Upheld Against NICE Recommendation in England
- CUV103 Singaporean Phase II vitiligo study results
- US FDA sets PDUFA date for SCENESSE
- US FDA extends PDUFA date for SCENESSE
- CLINUVEL declares Full Year Dividend
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals